Roni Mamluk, PhD is a senior biopharmaceutical executive with 16 years of experience in drug development companies and background in all aspects of R&D, general management and fundraising. Prior to Ayala, Roni was at Chiasma (NASDAQ: CHMA), a biopharmaceutical company focused on orphan diseases where she fulfilled multiple positions including CEO (2013-2015). She is an inventor of their oral delivery technology and led the development of their lead product through all stages of development, including NDA submission. She was a key player in fundraising for the company, including several private financing rounds and led a $70 million crossover financing and a successful IPO of over $100 million in 2015. Roni is now a board member at Chiasma. Prior to that, she was heading preclinical development of an oncology product at Adnexus (which was later acquired by Bristol-Myers Squibb (NYSE:BMY)) in Waltham, MA and did her post-doc at Children’s Hospital/Harvard Medical School in the field on angiogenesis prior to that. Roni received her PhD, summa cum laude from the Hebrew University in Jerusalem.